Why Oxford BioMedica has rallied 45% in a week
Investors are getting understandably excited about a potentially massive breakthrough in the treatment of leukaemia. A new treatment called CTL019 is edging closer to regulatory approvals with the US Food and Drug Administration...
03 July 2017
